Anti-beta-2 glycoprotein i epitope specificity: From experimental models to diagnostic tools

Lupus

Volumn 25, Issue 8, 2016, Pages 905-910

  Meroni, P L ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

Author keywords

Anti phospholipid antibodies; anti phospholipid syndrome; beta 2 glycoprotein I; miscarriages; thrombosis; 2GPI domains

Indexed keywords

AUTOANTIBODY; BETA2 GLYCOPROTEIN 1 ANTIBODY; EPITOPE; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; BETA2 GLYCOPROTEIN 1; BIOLOGICAL MARKER;

ANTIGEN BINDING; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; ASSAY; ASYMPTOMATIC DISEASE; CONFORMATIONAL TRANSITION; DIAGNOSTIC TEST; ENDOTHELIUM; HIGH RISK PATIENT; HUMAN; IMMUNOPATHOLOGY; IN VIVO STUDY; INFECTION; PATHOPHYSIOLOGY; PLACENTA; PREGNANCY; PRIORITY JOURNAL; ABORTION, SPONTANEOUS; ANIMAL; ANTIBODY SPECIFICITY; BLOOD; COMPLICATION; DISEASE MODEL; FEMALE; IMMUNOLOGY; MOUSE; THROMBOSIS;

ABORTION, SPONTANEOUS; ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIBODY SPECIFICITY; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; BIOMARKERS; DISEASE MODELS, ANIMAL; EPITOPES; FEMALE; HUMANS; MICE; PREGNANCY; THROMBOSIS;

EID: 84973333101     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203316641772     Document Type: Article

References (33)

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemostasis 2006; 4: 295-306.
2. Meroni PL, Borghi MO, Raschi E, Tedesco F,. Pathogenesis of antiphospholipid syndrome: Understanding the antibodies. Nat Rev Rheumatol 2011; 7: 330-339.
3. Giannakopoulos B, Krilis SA,. The pathogenesis of the antiphospholipid syndrome. N Engl J Med 2013; 368: 1033e44-1033e44.
4. Meroni PL, Chighizola CB, Rovelli F, Gerosa M,. Antiphospholipid syndrome in 2014: More clinical manifestations, novel pathogenic players and 2 emerging biomarkers. Arthritis Res Ther 2014; 16: 209-209.
5. De Groot PG, Meijers JC,. β(2)-Glycoprotein I: evolution, structure and function. J Thromb Haemostasis 2011; 9: 1275-1284.
6. Hollan I, Meroni PL, Ahearn JM, et al. Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun Rev 2013; 12: 1004-1015.
7. 2-glycoprotein I is inhibited by protein H and M1 protein from Streptococcus pyogenes. Mol Microbiol 2007; 67: 482-492.
8. 2-glycoprotein I: a novel component of innate immunity. Blood 2011; 117: 6939-6947.
9. Salem D, Subang R, Laplante P, Levine JS, Rauch J,. The dual role of innate immunity in antiphospholipid syndrome and systemic lupus erythematosus. Lupus 2014; 23: 1327-1331.
10. Chighizola CB, Raschi E, Borghi MO, Meroni PL,. Update on the pathogenesis and treatment of the antiphospholipid syndrome. Curr Opin Rheumatol 2015; 27: 476-482.
11. Agostinis C, Biffi S, Garrovo C, et al. In vivo distribution of β2 glycoprotein I under various pathophysiologic conditions. Blood 2011; 118: 4231-4238.
12. Raschi E, Chighizola CB, Grossi C, et al. β2-glycoprotein I, lipopolysaccharide and endothelial TLR4: three players in the two hit theory for anti-phospholipid-mediated thrombosis. J Autoimmun 2014; 55: 42-50.
13. Meroni PL, Macor P, Durigutto P, et al. Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery. Blood 2016; 127: 365-367.
14. D'Ippolito S, Meroni PL, Koike T, Veglia M, Scambia G, Di Simone N,. Obstetric antiphospholipid syndrome: a recent classification for an old defined disorder. Autoimmun Rev 2014; 13: 901-908.
15. Robertson SA, Roberts CT, van Beijering E, et al. Effect of beta2-glycoprotein I null mutation on reproductive outcome and antiphospholipid antibody-mediated pregnancy pathology in mice. Mol Hum Reprod 2004; 10: 409-416.
16. Poulton K, Ripoll VM, Pericleous C, et al. Purified IgG from patients with obstetric but not IgG from non-obstetric antiphospholipid syndrome inhibit trophoblast invasion. Am J Reprod Immunol 2015; 73: 390-401.
17. Shoenfeld Y, Krause I, Kvapil F, et al. Prevalence and clinical correlations of antibodies against six beta2-glycoprotein-I-related peptides in the antiphospholipid syndrome. J Clin Immunol 2003; 23: 377-383.
18. 2-glycoprotein I to determine fine antibody specificity of antiphospholipid autoantibodies. J Immunol 2002; 169: 7097-7103.
19. De Laat B, Derksen RH, van Lummel M, et al. Pathogenic anti-beta2 glycoprotein I antibodies recognize domain I of beta-2 glycoprotein I only after a conformational change. Blood 2006; 107: 1916-1924.
20. Pelkmans L, Kelchtermans H, de Groot PG, et al. Variability in exposure of epitope G40-R43 of domain I in commercial anti-beta2-glycoprotein I IgG ELISAs. PLoS One 2013; 8: e71402-e71402.
21. Ioannou Y, Pericleous C, Giles I, Latchman DS, Isenberg DA, Rahman A,. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum 2007; 56: 280-290.
22. Chighizola CB, Gerosa M, Meroni PL,. New tests to detect antiphospholipid antibodies: anti-domain I beta-2-glycoprotein-I antibodies. Curr Rheumatol Rep 2014; 16: 402-402.
23. Agostinis C, Durigutto P, Sblattero D, et al. A non-complement-fixing antibody to β2 glycoprotein I as a novel therapy for antiphospholipid syndrome. Blood 2014; 29; 123: 3478-3487.
24. 2-glycoprotein I: proof of concept. J Thromb Haemostasis 2009; 7: 833-842.
25. Pengo V, Ruffatti A, Tonello M, et al. Antibodies to Domain 4/5 (Dm4/5) of β2-glycoprotein 1 (β2GP1) in different anti-phospholipid (aPL) antibody prof iles. Thromb Res 2015; 136: 161-163.
26. Pengo V, Ruffatti A, Tonello M, et al. Antiphospholipid syndrome: antibodies to Domain 1 of β2-glycoprotein 1 correctly classify patients at risk. J Thromb Haemostasis 2015; 13: 782-787.
27. Mondejar R, González-Rodríguez C, Toyos-Sáenz de Miera FJ, et al. Role of antiphospholipid score and anti-β2-glycoprotein I Domain I autoantibodies in the diagnosis of antiphospholipid syndrome. Clin Chim Acta 2014; 431: 174-178.
28. De Laat B, Pengo V, Pabinger I, et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemostasis 2009; 7: 1767-1773.
29. Zuily S, De Laat B, Regnault V, et al. Autoantibodies against domain I of beta2-glycoprotein indicate an increased risk for thrombosis in antiphospholipid patients. A prospective cohort study. Arthritis Rheum 2013; 65: S1130-S1130.
30. Agmon-Levin N, Seguro L, Rosario C, et al. Anti-β2GPI-DI antibodies are a marker of APS severity. Arthritis Rheum 2013; 65: S1-S1.
31. Navid Z, Khamashta MA, Atsumi T, et al. Autoantibodies targeting domain 1 of beta 2 glycoprotein I as promising marker in the diagnosis and risk stratification of the antiphospholipid syndrome. Arthritis Rheum 2013; 65: S4-S4.
32. Andreoli L, Nalli C, Motta M, et al. Anti-β2-glycoprotein I IgG antibodies from 1-year old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason of their innocent profile? Ann Rheum Dis 2011; 70: 380-383.
33. Andreoli L, Chighizola CB, Nalli C, et al. Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against β2-glycoprotein I domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome. Arthritis Rheumatol 2015; 67: 2196-2204.